There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand
It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark.
Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting
CSL Behring’s haemophilia B gene therapy Hemgenix has become the first drug to be authorised for use under France’s recently-introduced ‘direct access’ programme, which ai
Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported
CSL Behring's recently approved gene therapy for haemophilia B Hemgenix has joined the swelling ranks of new medicines that are bundled with a companion app to support the